UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

DNA replication origins retain mobile licensing proteins

Nature communications, 2021-03, Vol.12 (1), p.1908-1908, Article 1908

2021

Volltextzugriff (PDF)

A Biophysics Toolbox for Reliable Data Acquisition and Processing in Integrated Force–Confocal Fluorescence Microscopy

ACS photonics, 2024-04, Vol.11 (4), p.1592-1603

2024

Volltextzugriff (PDF)

Principles and best practices of optimizing a micromirror-based multicolor TIRF microscopy system

Optics communications, 2023-07, Vol.538, p.129474, Article 129474

2023

Volltextzugriff (PDF)

Enhancement of image quality and imaging depth with Airy light-sheet microscopy in cleared and non-cleared neural tissue

Biomedical optics express, 2016-10, Vol.7 (10), p.4021-4033

2016

Volltextzugriff (PDF)

Global correction of optical distortions in multicolor single-molecule microscopy using Zernike polynomial gradients

Optics express, 2021-12, Vol.29 (25), p.42251

2021

Volltextzugriff (PDF)

Unprecedented tunability of riboswitch structure and regulatory function by sub-millimolar variations in physiological Mg2

Nucleic acids research, 2019-07, Vol.47 (12), p.6478-6487

2019

Volltextzugriff (PDF)

Structure and Functional Dynamics of Fluoride-Sensing Riboswitches

Biophysical journal, 2013-01, Vol.104 (2), p.411a-411a

2013

Volltextzugriff (PDF)

Light-sheet microscopy with attenuation-compensated propagation-invariant beams

Science advances, 2018-04, Vol.4 (4), p.eaar4817-eaar4817

2018

Volltextzugriff (PDF)

Fluorescence tools to investigate riboswitch structural dynamics

Biochimica et biophysica acta. Gene regulatory mechanisms, 2014-10, Vol.1839 (10), p.1005-1019

2014

Volltextzugriff (PDF)

Using sm-FRET and denaturants to reveal folding landscapes

Methods in enzymology, 2014, Vol.549, p.313

2014

Volltextzugriff (PDF)

How the lysine riboswitch folds

McCluskey, Kaley A

2015

Volltextzugriff (PDF)

Single-molecule fluorescence of nucleic acids

Methods in molecular biology (Clifton, N.J.), 2014, Vol.1076, p.759

2014

Volltextzugriff (PDF)

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

Neurology, 2015-01, Vol.84 (3), p.280-286

2015

Volltextzugriff (PDF)

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

Clinical cancer research, 2015-08, Vol.21 (16), p.3610-3618

2015

Volltextzugriff (PDF)

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Clinical cancer research, 2021-02, Vol.27 (4), p.1048-1057

2021

Volltextzugriff (PDF)

Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization

Journal of clinical oncology, 2023-12, Vol.41 (36), p.5524-5535

2023

Volltextzugriff (PDF)

NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii138-ii139

2020

Volltextzugriff (PDF)

CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii40-ii40

2020

Volltextzugriff (PDF)

NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Suppl 2), p.ii138-ii139

2020

Volltextzugriff (PDF)

CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi68-vi69

2021

Volltextzugriff (PDF)

CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION

Neuro-oncology (Charlottesville, Va.), 2021-11, Vol.23 (Supplement_6), p.vi59-vi59

2021

Volltextzugriff (PDF)

CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii43-ii44

2020

Volltextzugriff (PDF)

CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION

Neuro-oncology (Charlottesville, Va.), 2020-11, Vol.22 (Supplement_2), p.ii44-ii44

2020

Volltextzugriff (PDF)

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results

Journal of clinical oncology, 2014-05, Vol.32 (15_suppl), p.2027-2027

2014

Volltextzugriff (PDF)

Preliminary Data from a Multicenter, Phase II, Randomized, Non-Comparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly-Diagnosed Glioblastoma (GBM) (S45.006)

Neurology, 2012-04, Vol.78 (Meeting Abstracts 1), p.S45-S45.006

2012

Volltextzugriff (PDF)

1 – 25 von 25

Suche als RSS-Feed

Aktive Filter

SpracheEnglisch

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(22)
Mit Volltextzugriff
(18)

Publikationsform

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

DNA replication origins retain mobile licensing proteins

A Biophysics Toolbox for Reliable Data Acquisition and Processing in Integrated Force–Confocal Fluorescence Microscopy

Principles and best practices of optimizing a micromirror-based multicolor TIRF microscopy system

Enhancement of image quality and imaging depth with Airy light-sheet microscopy in cleared and non-cleared neural tissue

Global correction of optical distortions in multicolor single-molecule microscopy using Zernike polynomial gradients

Unprecedented tunability of riboswitch structure and regulatory function by sub-millimolar variations in physiological Mg2

Structure and Functional Dynamics of Fluoride-Sensing Riboswitches

Light-sheet microscopy with attenuation-compensated propagation-invariant beams

Fluorescence tools to investigate riboswitch structural dynamics

Using sm-FRET and denaturants to reveal folding landscapes

How the lysine riboswitch folds

Single-molecule fluorescence of nucleic acids

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma

A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients

Randomized Phase II and Biomarker Study of Pembrolizumab plus Bevacizumab versus Pembrolizumab Alone for Patients with Recurrent Glioblastoma

Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization

NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

CTIM-32. PHASE II AND BIOMARKER STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA PATIENTS

NCOG-44. NEUROLOGIC ASSESSMENT IN NEURO-ONCOLOGY (NANO) SCALE IN A PHASE II STUDY OF PEMBROLIZUMAB OR PEMBROLIZUMAB PLUS BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA

CTNI-40. EVALUATING FEASIBILITY AND EFFICIENCY OF PHASE II ADAPTIVE PLATFORM TRIAL DESIGNS BASED ON THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGhT) EXPERIENCE

CTNI-05. PRELIMINARY RESULTS OF THE NERATINIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION

CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL

CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION

Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma: Final results

Preliminary Data from a Multicenter, Phase II, Randomized, Non-Comparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly-Diagnosed Glioblastoma (GBM) (S45.006)

Aktive Filter

Suchergebnisse filtern